Tagged with R&D

China Ronald Tam, CFO of XTALPI, delves into the company’s evolution from its MIT origins to becoming a global leader in AI-driven drug discovery. Tam discusses the strategic decision to expand operations to China and globally, leveraging advanced technologies like quantum physics, AI, and robotics to revolutionize drug and materials discovery.…

Global The 2024 Nobel Prize in Physiology or Medicine has been awarded to Victor Ambros and Gary Ruvkun, key figures in the development of microRNA; miniscule RNA molecules that enable cells to control which proteins they produce.   The Nobel Assembly of Sweden’s Karolinska Institute, which selects the prize’s winner said…

Switzerland World-renowned oncologist Professor Susan Gasser outlines the innovative public-private partnership model in place at the ISREC Foundation at the AGORA Cancer Research Center in Lausanne. The unique model of ISREC/AGORA involves a reversal of the typical PPP structure, where the private foundation builds infrastructure and invites public institutions to collaborate,…

Switzerland Dr Frank Ruhli discusses the importance of attracting top talent and fostering academic freedom as key factors in achieving research excellence. Ruhli highlights his collaborative leadership style, significant achievements like establishing the One Health Institute, the value of international partnerships in advancing interdisciplinary medical research, and some of the key…

Switzerland Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s ‘Pharma Strategy 2030’ aims to solidify Switzerland’s leadership in R&D and healthcare sustainability.   Our vision is not just about…

Global In conversation at ESMO 2024 in Barcelona, Astellas Chief Medical Officer Tadaaki Taniguchi lays out some of the company’s most promising recent oncology data, his hopes around how Astellas’ modality-based strategy will ultimately bring “meaningfully differentiated” therapies to patients, and why next-generation treatments stand to reshape the cancer care paradigm.…

France In conversation at ESMO 2024, Pierre Fabre’s R&D Head Francesco Hofmann outlines some of the key data readouts for the company’s oncology portfolio from this year’s conference, how it is looking to expand its R&D portfolio via business development deals and biotech partnerships, and the spaces in which a mid-sized…

China The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director Renaud Gabay discusses how member companies are leveraging synchronized approvals to accelerate access; the evolution of China’s regulatory framework that…

Mexico Francisco Chavez from Thermo Fisher Scientific explains the company’s global mission to advance science and healthcare, with a particular focus on Latin America. Chavez highlights Thermo Fisher’s significant investment in R&D and its strategic approach to addressing regional healthcare challenges through public-private partnerships.   Our commitment is to create a…

Hong Kong Hong Kong needs to capitalise on its strong fundamentals to establish itself as a clinical research hotspot within APAC and support its transition into China’s innovation and technology hub. Does a new one-stop-shop for clinical trials across the Greater Bay Area hold the key?   Clinical trial numbers are skyrocketing…

Hong Kong Dr Jeremy Teoh highlights the importance of Hong Kong’s role in global urology research, emphasizing collaborations with international institutions and the Greater Bay Area. Despite the challenges of Hong Kong’s smaller scale, its strategic position allows it to bridge Eastern and Western medical practices, elevating research standards globally. Dr Teoh…

Saudi Arabia Attracting, developing, and retaining talented workers – both Saudi and foreign – is perhaps the key sticking point to Saudi Arabia achieving its ambitious transformation targets. Thus far this has involved both ‘carrot’ and ‘stick’ initiatives, ranging from tax incentives and specialised training programs on one side, to mandatory ‘Saudization’…